7/9/2013

Novartis' secukinumab worked better than Amgen's Enbrel in clearing the skin of people with moderate to severe plaque-type psoriasis in a Phase III trial. Novartis plans to submit the drug for regulatory review by year-end.

Full Story:
Reuters

Related Summaries